A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs. Issue 3 (8th March 2019)

• Record Type: Journal Article
• Authors: Evans, Liam A.; Tansey, Colleen; Wiebe, Melissa; Sloan, Caroline Q.; Patlogar, Jeffrey E.; Northcutt, Sarah; Murphy, Lisa A.; Nakamura, Reid K.
• Is Part Of: Veterinary medicine and science. Volume 5:Issue 3(2019)
• Page Start: 317
• Page End: 324
• Publication Date: 2019-03-08
• Subjects: coagulation -- embolism -- thromboembolism; Veterinary medicine -- Periodicals; Animal Diseases; Veterinary medicine; Periodicals; Periodicals; 636.08905
• DOI: 10.1002/vms3.161
• Languages: English
• ISSNs: 2053-1095

Abstract

Abstract: The purpose of this study was to determine the effect of rivaroxaban (RIV) on haemostatic parameters assessed by prothrombin time (PT), activated partial thromboplastin time (aPTT) and kaolin‐activated thromboelastography (TEG) in apparently healthy dogs administered 1 mg kg −1 orally once daily for 1 week. Eleven dogs had a baseline complete blood count (CBC), fibrinogen, platelet count, serum chemistry profile, PT, aPTT, and TEG performed. Each dog was then administered approximately 1.0 mg kg −1 of RIV orally once daily for 1 week and the CBC, fibrinogen, platelet count, serum chemistry profile, PT, aPTT, and TEG was re‐evaluated. Any side effects attributed to RIV were noted at this time. One dog was excluded due to identification of a macrocytic thrombocytopenia on pre‐treatment blood work. The remaining 10 enrolled dogs completed the study. Dogs received a median dose of 1.02 mg kg −1 (range 0.94–1.17 mg kg −1 ) of RIV once daily and was associated with a significant increase in pulse, packed cell volume, total solids, platelet count, fibrinogen and a significant decrease in mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration. There was no significant change in PT, aPTT or any TEG parameters. The RIV appeared well tolerated with one dog having one episode of vomiting on day 4 but otherwise no other side effects were identified clinically or on recheck blood work. The results of this study suggests that RIV at a dose of 1 mg kg −1 orally once daily is safe and well tolerated but does not cause a significant prolongation of PT, aPTT or TEG parameters. Abstract : This study failed to identify a significant change in thromboelastographic parameters in apparently healthy dogs receiving rivaroxaban at 1 mg/kg orally once daily for one week.